Please assess the completion status of the following clinical trial:

Trial Title: Exenatide in Extreme Pediatric Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index \> or = 1.2 times the 95th percentile (based on gender and age) or Body mass index \> or = 35 kg/m2~* 12-19 years old~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Previous (within 3-months) or current use of weight loss medication (patients may undergo washout)~* Previous bariatric surgery~* Recent initiation (within 1-month) of anti-hypertensive or lipid medication~* Previous (within 1-month) or current use of medication to treat insulin resistance or hyperglycemia (patients may undergo washout)~* Major psychiatric disorder~* Pregnant or planning to become pregnant~* Tobacco use~* Liver/renal dysfunction~* History of pancreatitis~* Obesity associated with genetic disorder~* Hyperthyroidism or uncontrolled hypothyroidism~* Uncontrolled hypertriglyceridemia (=300 mg/dL)~* Current eating disorder~* Previous (within 3-months) or current use of drugs associated with weight gain (e.g. steroids/anti-psychotics)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide, then Open-Label Exenatide (Type: EXPERIMENTAL): Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
- Placebo, then Open Label Exenatide (Type: PLACEBO_COMPARATOR): Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).